Patent 11268077 was granted and assigned to Vertex Pharmaceuticals on March, 2022 by the United States Patent and Trademark Office.
Materials and methods for treating a patient with hemoglobinopathy, both ex vivo and in vivo and materials and methods for deleting at least a portion of a human beta globin locus on chromosome 11 in a human cell by genome editing and thereby increasing the production of fetal hemoglobin (HbF).